Sequencing and characterization of the porcine α-galactosidase A gene: towards the generation of a porcine model for Fabry disease.

Molecular Biology Reports
Makoto YoshimitsuT Takenaka

Abstract

Fabry disease is an inherited lysosomal disorder caused by a deficiency of alpha-galactosidase A (α-gal A). The systemic accumulation of substrate, mainly globotriaosylceramide (Gb3), results in organ failure. Although Gb3 accumulation has been observed in an α-gal A-deficient mouse model, important clinical manifestations were not seen. The pursuit of effective treatment for Fabry disease through gene therapy, for example, has been hampered by the lack of a relevant large animal model to assess the efficacy and safety of novel therapies. Towards assembling the tools to generate an alternative animal model, we have sequenced and characterized the porcine ortholog of the α-gal A gene. When compared to the human α-gal A, the porcine α-gal A showed a high level of homology in the coding regions and located at chromosome Xq22. Cell lysate and supernatants from Fabry patient-derived fibroblasts transduced with a lentiviral vector (LV) carrying the porcine α-gal A cDNA (LV/porcine α-gal A), showed high levels of α-gal A activity and its enzymological stability was similar to that of human α-gal A. Uptake of secreted porcine α-gal A was observed into non-transduced cells and was partially inhibited by soluble mannose-6-phosphate. Furt...Continue Reading

References

May 25, 1967·The New England Journal of Medicine·R O BradyL Laster
May 5, 1981·Clinica Chimica Acta; International Journal of Clinical Chemistry·J S MayesM L Donaldson
Feb 27, 1997·Nature·I WilmutK H Campbell
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·T OhshimaA B Kulkarni
May 20, 1999·Nature Biotechnology·A BaguisiY Echelard
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·T TakenakaJ A Medin
Sep 19, 2000·Nature·I A PolejaevaK H Campbell
Feb 28, 2001·Proceedings of the National Academy of Sciences of the United States of America·S C JungP Qasba
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·G QinJ A Medin
Mar 30, 2002·Nature Biotechnology·Patrick ChesnéJean-Paul Renard
Oct 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Hiroshi TakahashiTakashi Shimada
Mar 9, 2004·Journal of Molecular Biology·Scott C Garman, David N Garboczi
Nov 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·Makoto YoshimitsuJeffrey A Medin
Aug 5, 2005·Nature·Byeong Chun LeeWoo Suk Hwang
Apr 6, 2006·Developmental Biology·Ziyi LiJohn F Engelhardt
Oct 26, 2006·Circulation Journal : Official Journal of the Japanese Circulation Society·Makoto YoshimitsuJeffrey A Medin
Dec 28, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Robin J ZieglerSeng H Cheng
Apr 13, 2007·Molecular Reproduction and Development·Kazuchika MiyoshiMitsutoshi Yoshida
Mar 8, 2008·The Journal of Clinical Investigation·Xingshen SunJohn F Engelhardt
Sep 27, 2008·Science·Christopher S RogersMichael J Welsh
Dec 23, 2008·Cell Stem Cell·Jing LiaoLei Xiao
Apr 21, 2009·The Journal of Biological Chemistry·Miguel A EstebanDuanqing Pei
Mar 1, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Robin J ZieglerSeng H Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.